Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction

Journal of Sexual Medicine

Volumn 13, Issue 3, 2016, Pages 305-316

  Santoro, Nanette ^a   Worsley, Roisin ^b   Miller, Karen K ^c   Parish, Sharon J ^d   Davis, Susan R ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Centre of Cardiovascular Research Education in Therapeutics School of Public Health and Preventive Medicine   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Estrogen; Female Sexual Dysfunction; Hormones

Indexed keywords

AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTRONE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; OSPEMIFENE; PLACEBO; PROGESTERONE; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TIBOLONE; AGENTS USED INTRAVAGINALLY; CONTRACEPTIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTHRALGIA; ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; DYSPAREUNIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE SEXUAL DYSFUNCTION; FEMALE SEXUAL FUNCTION INDEX; HOT FLUSH; HUMAN; HYSTERECTOMY; LIBIDO DISORDER; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; SEXUAL FUNCTION; TURNER SYNDROME; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA PAIN; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VASOMOTOR DISORDER; DRUG EFFECTS; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRACTICE GUIDELINE; PROCEDURES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; WOMEN'S HEALTH;

ADMINISTRATION, INTRAVAGINAL; CONTRACEPTIVE AGENTS, FEMALE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; WOMEN'S HEALTH;

EID: 84964413432     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1016/j.jsxm.2015.11.015     Document Type: Article

References (96)

1. Santen R.J., Allred D.C., Ardoin S.P., et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010, 95:S7.
2. de Villiers T.J., Gass M.L., Haines C.J., et al. Global consensus statement on menopausal hormone therapy. Maturitas 2013, 74:391.
3. Simpson E.R., Davis S.R. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 2001, 142:4589.
4. Zumoff B., Strain G.W., Miller L.K., et al. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995, 80:1429.
5. Burger H.G., Dudley E.C., Cui J., et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000, 85:2832.
6. Santoro N., Torrens J., Crawford S., et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005, 90:4836.
7. Lobo R. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 1987, 14:143.
8. Slater C., Hodis H., Mack W., et al. Markedly elevated levels of estrone sulfate after long term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001, 8:200.
9. Dunn J.F., Nisula B.C., Rodboard D. Transport of steroid hormones. Binding of 21 endogenous steroids to both testosterone-binding globulin and cortico-steroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981, 53:58.
10. Raisz L.G., Wiita B., Artis A., et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1995, 81:37.
11. Bixo M., Backstrom T., Winblad B., et al. Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J Steroid Biochem Mol Biol 1995, 55:297.
12. Roselli C.E., Resko J.A. Aromatase activity in the rat brain: hormone regulation and sex differences. J Steroid Biochem Mol Biol 1993, 44:499.
13. Hamann S., Stevens J., Vick J.H., et al. Brain responses to sexual images in 46,XY women with complete androgen insensitivity syndrome are female-typical. Horm Behav 2014, 66:724.
14. Bryant D.N., Sheldahl L.C., Marriott L.K., et al. Multiple pathways transmit neuroprotective effects of gonadal steroids. Endocrine 2006, 29:199.
15. Moss R.L., McCann S.M. Action of luteinizing hormone-releasing factor (lrf) in the initiation of lordosis behavior in the estrone-primed ovariectomized female rat. Neuroendocrinology 1975, 17:309.
16. Mani S.K., Allen J.M.C., Rettori V., et al. Nitric oxide mediates sexual behaviour in female rats. Proc Nat Acad Sci U S A 1994, 91:6468.
17. Ogawa S., Chester A.E., Hewitt S.C., et al. Abolition of male sexual behaviours in mice lacking estrogen receptors alpha and beta. Proc Nat Acad Sci U S A 2000, 97:14737.
18. Christensen A., Micevych P. A novel membrane estrogen receptor activated by STX induces female sexual receptivity through an interaction with mgluR1a. Neuroendocrinology 2013, 97:363.
19. Etgen A.M., Ansonoff M.A., Quesda A. Mechanisms of ovarian steroid regulation of norepinephrine receptor-mediated signal transduction in the hypothalamus: implications for female reproductive physiology. Horm Behav 2001, 42:169.
20. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801.
21. Semmens J., Tsai C., Semmens E., Loadholt C. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol 1985, 66:15.
22. Furchgott R., Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373.
23. Biegelsen E., Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis 1999, 10:241.
24. Celemajer D.S., Sorensen K., Georgakopoulos D., et al. Cigarette smoking is associated with dose-related and potential reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993, 88:2149.
25. Celemajer D.S., Sorensen K., Gooch V., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111.
26. Davis S.R., Goldstat R., Newman A., et al. Differing effects of low dose estrogen and progestin replacement therapy and pravastatin in hypercholesterolemic postmenopausal women. Climacteric 2002, 5:341.
27. Shifren J.L., Monz B.U., Russo P.A., et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008, 112:970.
28. Nappi R.E., Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009, 6:603.
29. Nappi R.E., Davis S.R. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012, 15:267.
30. Avis N.E., Brockwell S., Randolph J.F., et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009, 16:442.
31. Fistarol S.K., Itin P.H. Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol 2013, 14:27.
32. Davison S.L., Bell R., Donath S., et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005, 90:3847.
33. Aziz A., Brannstrom M., Bergquist C., et al. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005, 83:1021.
34. Nathorst-Boos J., von Schoultz B., Carlstrom K. Elective ovarian removal and estrogen replacement therapy: effects on sexual life, psychological well being and androgen status. J Psychosom Obset Gynaecol 1993, 14:283.
35. Rhodes J.C., Kjerulff K.H., Langenberg P.W., et al. Hysterectomy and sexual functioning. JAMA 1999, 282:1934.
36. Shifren J.L., Avis N.E. Surgical menopause: effects on psychological well-being and sexuality. Menopause 2007, 14:586.
37. Aziz A., Bergquist C., Brannstrom M., et al. Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy. Acta Obstet Gynecol Scand 2005, 84:854.
38. Erekson E.A., Martin D.K., Zhu K., et al. Sexual function in older women after oophorectomy. Obstet Gynecol 2012, 120:833.
39. Gracia C.R., Samuel M.D., Freeman E.W., et al. Predictors of decreased libido in women during the late reproductive years. Menopause 2004, 11:144.
40. Gracia C.R., Freeman E.W., Sammel M.D., et al. Hormones and sexuality during transition to menopause. Obstet Gynecol 2007, 109:831.
41. Freeman E.W., Sammel M.D., Lin H., et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007, 110:230.
42. Dennerstein L., Dudley E., Burger H. Are changes in sexual functioning during midlife due to aging or menopause?. Fertil Steril 2001, 76:456.
43. Dennerstein L., Lehert P., Burger H. The relative effects of hormone and relationship factors on sexual function of women through the natural menopause transition. Fertil Steril 2005, 84:174.
44. Modelska K., Litwack S., Ewing S.K., et al. Endogenous estrogen levels affect sexual function in elderly post-menopausal women. Maturitas 2004, 49:124.
45. Randolph J.F., Zheng H., Avis N.E., et al. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab 2015, 100:258.
46. Cawood E.H.H., Bancroft J. Steroid hormone, the menopause, sexuality and well-being of women. Psychol Med 1996, 26:925.
47. Gallicchio L., Schilling C., Tomic D., et al. Correlates of sexual functioning among mid-life women. Climacteric 2007, 10:132.
48. Avis N.E., Stellato R., Crawford S., et al. Is there an association between menopause status and sexual functioning?. Menopause 2000, 7:297.
49. Dennerstein L., Burrows G.D., Wood C., et al. Hormones and sexuality: effect of estrogen and progestogen. Obstet Gynecol 1980, 56:316.
50. Davis S.R., Panjari M., Robinson P.J., et al. Menopausal symptoms in breast cancer survivors nearly 6 years post diagnosis. Menopause 2014, 21:1075.
51. Long C.Y., Liu C.M., Hsu S.C., et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006, 13:737.
52. Celik H., Gurates B., Yavuz A., et al. The effect of hysterectomy and bilaterally salpingo-oophorectomy on sexual function in post-menopausal women. Maturitas 2008, 61:358.
53. Huang A., Yaffe K., Vittinghoff E., et al. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. Am J Obstet Gynecol 2008, 198:265.e1.
54. Nathorst-Boos J., Wiklund I., Mattsson L.-A., et al. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynecol Scand 1993, 72:565.
55. Gast M.J., Freedman M.A., Vieweg A.J., et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009, 16:247.
56. Taylor HS, Harman MS, Pal L, et al. Effects of oral vs transdermal estrogen vs placebo on sexual function over time in the Kronos Early Estrogen Prevention Study (KEEPS). Presented at: Proceedings of the North American Menopause Society Annual Meeting. 2012. October 3-6, 2012, Orlando, FL.
57. Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2014, 17:1.
58. Kendall A., Dowsett M., Folkerd E., et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006, 17:584.
59. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014, 123:202.
60. Leiblum S., Bachmann G.A., Kemmann E., et al. The importance of sexual activity and hormones. JAMA 1983, 249:2195.
61. Coulam C.B., Adamson S.C., Annegers J.F. Incidence of premature ovarian failure. Obstet Gynecol 1986, 67:604.
62. van der Stege J.G., Groen H., van Zadelhoff S.J., et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008, 15:23.
63. Gravholt C.H., Svenstrup B., Bennett P., et al. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status. Clin Endocrinol (Oxf) 1999, 50:791.
64. Gravholt C.H., Hjerrild B.E., Mosekilde L., et al. Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol 2006, 155:583.
65. Rolstad S.G., Moller A., Bryman I., et al. Sexual functioning and partner relationships in women with turner syndrome: some empirical data and theoretical considerations regarding sexual desire. J Sex Marital Ther 2007, 33:231.
66. Carel J.C., Elie C., Ecosse E., et al. Self-esteem and social adjustment in young women with Turner syndrome-influence of pubertal management and sexuality: population-based cohort study. J Clin Endocrinol Metab 2006, 91:2972.
67. Kalantaridou S.N., Davis S.R., Nelson L.M. Premature ovarian failure. Endocrinol Metab Clin North Am 1998, 27:989.
68. Shelly W., Draper M.W., Krishnan V., et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008, 63:163.
69. Varras M., Polyzos D., Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003, 24:258.
70. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131.
71. Mortimer J.E., Boucher L., Baty J., et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999, 17:1488.
72. Panjari M., Bell R.J., Davis S.R. Sexual function after breast cancer. J Sex Med 2011, 8:294.
73. Speer J.J., Hillenberg B., Sugrue D.P., et al. Study of sexual functioning determinants in breast cancer survivors. Breast J 2005, 11:440.
74. Johansson H., Bonanni B., Mariette F., et al. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 2006, 98:167.
75. Modugno F., Ness R.B., Ewing S., et al. Effects of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol 2003, 101:353.
76. Parsons A., Merritt D., Rosen A., et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003, 101:346.
77. Pinkerton J.V., Shifren J.L., La Valleur J., et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003, 10:45.
78. Constantine G., Graham S., Portman D.J., et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015, 18:226.
79. Goldstein S.R., Bachmann G.A., Koninckx P.R., et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2013, 17:173.
80. Hadji P., Kauka A., Bauer T., et al. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric 2012, 15:460.
81. Gallicchio L., Macdonald R., Wood B., et al. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 2011, 130:569.
82. Kucherov A., Polotsky A.J., Menke M., et al. Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. Fertil Steril 2011, 95:2063.
83. Kaunitz A.M. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008, 358:1262.
84. Strufaldi R., Pompei L.M., Steiner M.L., et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010, 82:147.
85. Greco T., Graham C.A., Bancroft J., et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007, 76:8.
86. Graham C.A., Ramos R., Bancroft J., et al. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995, 52:363.
87. Guida M., Di Spiezio Sardo A., Bramante S., et al. Effects of two types of hormonal contraception-oral versus intravaginal-on the sexual life of women and their partners. Hum Reprod 2005, 20:1100.
88. Zimmerman Y., Eijkemans M.J., Coelingh Bennink H.J., et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014, 20:76.
89. Davis S.R., Bitzer J., Giraldi A., et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J Sex Med 2013, 10:3069.
90. Kloosterboer H. Tibolone: a steroid with tissue-specific mode of action. J Steroid Biochem Mol Biol 2001, 76:231.
91. Doren M., Rubig A., Coelingh Bennink H., et al. Differential effects of the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001, 75:554.
92. Hammar M., Christau S., Nathorst-Boos J., et al. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998, 105:904.
93. Swanson S.G., Drosman S., Helmond F.A., et al. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006, 13:917.
94. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008, 359:697.
95. Nijland E.A., Weijmar Schultz W.C., Nathorst-Boos J., et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008, 5:646.
96. Gartoulla P., Worsley R., Bell R.J., et al. Moderate-severe vasomotor and sexual symptoms remain problematic for 60-65 year old women. Menopause 2015, 22:694.